Sol-Gel Technologies (SLGL) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vogenx is the larger company by market cap ($263.6 million vs $229.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | VOGX |
|---|---|---|
| Share price | $70.05 | $17.75 |
| Market cap | $229.34M | $263.60M |
| 1-day change | -2.63% | +9.81% |
| YTD return | +70.73% | — |
| 1-year return | +75.52% | — |
| 5-year return | -22.85% | — |
| EPS (TTM) | $-5.61 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.97 | $38.41 |
| 52-week low | $28.81 | $12.95 |
| Distance from 52-week high | -28.50% | -53.80% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +117.70% | +209.95% |
| Average volume | 55.30K | 188.79K |
| Shares outstanding | 3.27M | 14.86M |
| Employees | 28 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
SLGL vs VOGX FAQ
Which is bigger, Sol-Gel Technologies or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $263.60M compared with $229.34M for Sol-Gel Technologies (SLGL).
Are Sol-Gel Technologies and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.